Group items tagged

Dermal fillers, also known as injectable facial fillers, can be an effective way to reduce the appearance of wrinkles and fine lines, restore facial volume, and enhance certain features. While dermal fillers are generally safe, it's important to know about the potential benefits and side effects before you decide if they're right for you. In this blog post, we will look at the potential benefits and side effects of dermal fillers. We will also provide some tips for preparing for your treatment and ensuring a safe, successful procedure. So if you're considering dermal fillers, read on to learn more! HOW ARE DERMAL FILLERS INJECTED? Dermal fillers are typically injected directly into the skin with a small needle. Your doctor or injector will decide how much filler should be used and where it should be placed based on your desired outcome. In general, people who want to reduce wrinkles or enhance certain features may need more filler than those who just want to restore the volume in their face. Since they are injected under the skin, dermal fillers are minimally invasive and require little downtime after the procedure. It usually takes around 30 minutes to perform the procedure. Additionally, you may experience some swelling, bruising, and tenderness in the area where the filler was injected. This should subside over the next few days.

HGH injections are very useful for the body but they have many side-effects as well. Human Growth Hormone serves as a savior for the aging community. In case, HGH supplements don't work, HGH injections are the best alternative for you. HGH Injections have also been used to help the children with their growth tissues. These injections are also useful for the HIV patients and people who have problem of bones such as osteoporosis.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the Committees of Advertising Practice (CAP) have issued a joint enforcement notice about the 'illegal' advertising of Kenalog injections on digital platforms. The notice warns all organisations offering Kenalog as a 'hay fever treatment' to stop advertising it in any of their social media or website advertising. "Kenalog is a prescription-only medicine (POM), which must not be directly or indirectly advertised to the public. Kenalog is not licensed for the treatment of hay fever in the UK, although it is offered by some beauty and aesthetics clinics, under the personal responsibility of an individual prescriber, and advertised widely on social media," said MHRA. "Now, advertisers must ensure that all references to Kenalog in the text, images or emojis on social media are removed, as well as commonly-used descriptive phrases for the jab such as 'hay fever injection' or hay fever jab' or any account names, testimonials or memes by 29 August 2022." After this date, the CAP's compliance team will remove non-compliant ads using targeted software and those who continue to promote it may be referred to the MHRA for further enforcement action.

The Department of Health and Social Care (DHSC) has notified pharmacies over the shortage of Buserelin (Suprefact) 5.5mg/5.5ml solution for injection vials is out of stock until mid-August 2022. Limited supply of Buserelin (Suprefact) 5.5mg/5.5ml solution for injection vials remains available in NHS Trusts and health boards. Buserelin (Suprecur) 5.5mg/5.5ml solution for injection vials are currently available, however, this stock is short dated (expires end of July) and further stock is expected mid-August 2022. Buserelin (Suprecur)150microgram/dose nasal spray is out of stock until late-December 2022. Limited supply remains available in NHS Trusts and Health Boards. Nafarelin (Synarel) 200microgram/dose nasal spray remains available but is currently unable to support an uplift in demand (until mid-August 2022 when it can support a partial uplift in demand).

British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.

Human growth hormone plays important roles in the body regarding growth and functioning. It is naturally produced in the brain and its level decreases with the person's age. HGH supplements, products, and injections are used to treat HGH deficiency. Human growth hormone injections are quite beneficial in treating growth hormone deficiency. Injectable HGH human growth hormone, also called somatropin, has a great role in growth of bones, cells, organs, and muscles.

Skin Lightening Injections - The skin Lightening injections, Skin Whitening Treatment, Skin Glow Treatment is the solution for you to get the radiant glow. Contact us now.

Novo Nordisk has launched PenCycle, a recycling initiative for pre-filled injection pens, designed to address the challenge of recycling injection pen devices. A first-of-its-kind scheme in the UK, covering FlexPen® and FlexTouch® used to dispense insulin and other medications, will have community pharmacies playing a key role. Users can return their devices to local participating community pharmacies or through pre-paid Royal Mail boxes or use an 'at home' collection pilot service for growth hormone pens. The pens will then be returned to Denmark where the plastic will be recycled into a range of items, such as chairs and lamps, the Danish multinational pharmaceutical company said.

Human growth hormone is a basic and essential part of human body that is essential for number of body functions. Its level reduces with age that causes many problems in the body. Number of supplements and injections are used for its treatment. Here we are examining the benefits and side effects of supplements Vs injections.

Several types of injectable wrinkle fillers in the market. Such as, Juvederm Glendale, Restylane, Restylane LYFT, Kybella chin treatment etc. Unlike Botox injections that relax the muscle under a wrinkle, injectable winkle fillers are soft tissue fillers.

Diamorphine 5mg and 10mg powder used for solution for injection ampoules will remain unavailable until February 2022, Department of Health and Social Care (DHSC) has said in an update. These injection ampoules are used to treat severe pain associated with surgical procedures, pain in the terminally ill, and to provide relief in acute pulmonary oedema. Diamorphine 30mg and 100mg ampoules are available, however, the stock is not enough to support an uplift in demand. Separately, the DHSC has extended the Medicine Supply Notification for Kolanticon gel, which is expected to remain unavailable until October 2022.

Living with diabetes can be difficult, but it is important to remember that you are not alone. Millions of people around the world are living with diabetes every day. This article will discuss some tips on how to better handle your diabetes. It will also provide information on the latest treatments and technologies available to help make managing your diabetes easier than ever before! 1) METHOD OF INSULIN DELIVERY There are a variety of methods for insulin delivery, each with its own benefits and drawbacks. One of the most common methods is injections. Insulin injections are quick and easy, and they allow you to have more control over your blood sugar levels. However, some people find them to be painful or inconvenient. As seen at DiaBettr, there are also insulin pens available that can make injections less painful and more convenient. Another method of insulin delivery is through an insulin pump. Insulin pumps are small, wearable devices that deliver insulin to your body constantly throughout the day. They are very effective at keeping your blood sugar levels in control, but they can be expensive and require a lot of maintenance.

In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised a new Johnson & Johnson drug in Britain. Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to six months of symptom control and a reduction in their risk of relapse with only two doses a year. It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous absorption of paliperidone palmitate over a six-month period. "Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication," said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.

Levomepromazine 25mg/1ml solution for injection will remain unavailable until the week commencing March 7,2022, Department of Health and Social Care (DHSC) said in an update. While alternative medicines for use in palliative care remain available in ample supply to support an uplift in demand, the date supply resumption of Levomepromazine is yet to be confirmed. The DHSC has sent a copy of this medicine supply notification to all pharmacy NHS email addresses. It further informed primary care providers that prescription validation has been temporarily implemented at wholesaler level.

The latest formulation of XGEVA (denosumab) is now available to patients in the UK, offering a more convenient treatment option for bone metastasis. It is the first product to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new International Recognition Procedure (IRP). Denosumab (XGEVA) is used to prevent serious bone-related complications resulting from bone metastasis in adults and to treat giant cell tumour of bone in both adults and adolescents. The medicine was authorised on 29 February 2024 as a 120 mg solution for injection in a prefilled syringe. In contrast to the current vial presentation, this simplifies the administration process, reducing the volume of liquid injected and lowering the risk of dosing errors. The product was authorised in 30 days by the MHRA, thanks to the new IRP that facilitated a rapid approval process.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution developed by Danish specialist LEO Pharma. This injectable solution contains 300 mg of tralokinumab in a 2 mL pre-filled pen and will be available for tralokinumab patients in the UK from early 2024. Tralokinumab is indicated for treating moderate-to-severe atopic dermatitis in adult and adolescent patients aged 12 and older who require systemic therapy, Leo Pharma said in a statement. It is a fully human monoclonal antibody developed to specifically bind to and inhibit the IL-13 cytokine. Previously, it was available in a 150 mg in 1 mL pre-filled syringe. According to Leo Pharma, the 300 mg tralokinumab in a 2 mL pre-filled pen offers a streamlined administration for both patients and prescribers. It begins with an initial 600 mg dose in two injections, followed by a single 300 mg maintenance dose administered every other week. "We're pleased that this simplified administration method for tralokinumab will soon benefit eligible atopic dermatitis patients in the UK. It aligns with our commitment to elevate the standard of care and support for individuals with skin conditions," said Leanne Walsh, Vice President and General Manager of UK and Ireland at LEO Pharma.

It has been reported that several Austrians have been taken to the hospital after injecting fake Ozempic, as confirmed by health regulator. Austria's Federal Office for Safety in Health Care (BASG) confirmed that the patients have suffered hypoglycaemia and seizures. It is believed that the injections contained insulin instead of the weight loss drug, semaglutide. The health regulator has urged doctors and patients to verify their medication stocks.

The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment. Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO). In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective. Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

Eli Lilly's weight-loss medicine Mounjaro, also known as tirzepatide, will be available in the UK within weeks as a four-dose pre-filled injection pen. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the drug to treat adults with type 2 diabetes and for weight management in obese patients. Branded as Mounjaro KwikPen, the injection is to be used together with a reduced-calorie diet and increased physical activity, the regulator said. "The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people's health, is clear. "This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month's treatment, of one dose per week," said Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access.

In our quest for perfect skin, the landscape of dermatology and skin care has evolved dramatically, offering breakthrough treatments and solutions. The pursuit of a blemish-free, radiant complexion is no longer a distant dream, thanks to advancements in medical aesthetics and skincare technology. From non-invasive procedures to tailor-made skincare regimens, individuals now have access to a plethora of options designed to target specific skin concerns. This article explores the cutting-edge treatments that promise to diminish imperfections and reveal flawless skin, transforming not just how we look but also how we feel about ourselves. Botox Injections Botox, or Botulinum toxin, has gained immense popularity for its ability to smooth out wrinkles and fine lines. It works by temporarily paralyzing the facial muscles responsible for creating these imperfections. The procedure involves injecting small amounts of the neurotoxin into targeted areas, such as the forehead, crow's feet, and frown lines between the brows. The effects of Botox typically last for three to four months, making it a popular choice for those seeking quick and noticeable results. The people at sdbotox.com note that it is also a popular preventative treatment for those looking to delay the formation of wrinkles. With consistent use, Botox can actually prevent fine lines and wrinkles from appearing in the first place, making it an attractive option for individuals in their late 20s and early 30s.